- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Biomotion Sciences Warrant (SLXNW)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/06/2026: SLXNW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -69.71% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.12 | 52 Weeks Range 0.01 - 0.18 | Updated Date 06/5/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 06/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -193.54% | Return on Equity (TTM) -116.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 996278 |
Shares Outstanding - | Shares Floating 996278 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Biomotion Sciences Warrant
Company Overview
History and Background
Biomotion Sciences Warrant refers to the warrants associated with Biomotion Sciences, a company that has undergone significant changes, including name changes and potential acquisitions. Information regarding its founding year and specific historical milestones is scarce and often intertwined with its successor entities or parent companies.
Core Business Areas
- Biomotion Sciences (Historical): Historically, Biomotion Sciences was involved in the development and commercialization of technologies related to biomotion analysis, often for applications in medical diagnostics and sports science. Specific product details and market reach from this era are not readily available.
Leadership and Structure
Information on the specific leadership and organizational structure of 'Biomotion Sciences Warrant' as a distinct entity is not readily available. This suggests it may be a historical financial instrument linked to a company that has since been acquired, merged, or significantly restructured.
Top Products and Market Share
Key Offerings
- Warrants for Biomotion Sciences: These are financial instruments that grant the holder the right, but not the obligation, to purchase shares of Biomotion Sciences at a specified price within a certain timeframe. Market share data or revenue attribution is not applicable as warrants are derivative instruments.
Market Dynamics
Industry Overview
The industry related to biomotion analysis and its applications has seen advancements in sensor technology, AI, and data analytics, leading to applications in healthcare, fitness, and rehabilitation. However, the specific market for Biomotion Sciences' historical offerings is difficult to ascertain.
Positioning
As warrants, Biomotion Sciences Warrant's positioning is entirely dependent on the performance and strategic direction of the underlying company (Biomotion Sciences or its successors). Without current operational data for Biomotion Sciences, its competitive positioning cannot be assessed.
Total Addressable Market (TAM)
The TAM for companies involved in biomotion analysis can be substantial, spanning healthcare diagnostics, sports performance, and rehabilitation technologies. Biomotion Sciences Warrant's specific position relative to this TAM is unquantifiable without information on the current status of the underlying company.
Upturn SWOT Analysis
Strengths
- Potential for high returns if the underlying stock performs well.
- Lower upfront investment compared to purchasing stock directly.
Weaknesses
- Limited liquidity for warrants.
- Expiration date creates a time-sensitive risk.
- Dependence on the performance of the underlying company.
- Complex financial instruments that may not be understood by all investors.
Opportunities
- Exploiting undervaluation of the underlying company's stock.
- Capitalizing on positive market sentiment towards the sector.
- Potential for significant gains if the underlying company experiences growth.
Threats
- Expiration of warrants without value if the stock price does not reach the strike price.
- Adverse movements in the underlying stock price.
- Dilution from future stock offerings by the underlying company.
- Changes in regulatory environments affecting the underlying business.
Competitors and Market Share
Key Competitors
Competitive Landscape
The competitive landscape for warrants is not defined by direct competitors in the same way as operating companies. Instead, the 'competitors' are essentially other derivative instruments or simply the underlying stock itself, and the success of the warrant is entirely tied to the success of the underlying company in its respective market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth of 'Biomotion Sciences Warrant' is contingent on the performance and growth of the underlying company. Without current operational data for Biomotion Sciences, this cannot be assessed.
Future Projections: Future projections for warrants are speculative and tied to the projected growth and stock price movements of the underlying company. Analyst estimates for 'Biomotion Sciences Warrant' are not separately available.
Recent Initiatives: Recent strategic initiatives would pertain to the underlying company, Biomotion Sciences. Information on such initiatives under this specific name is not readily available.
Summary
Biomotion Sciences Warrant represents a derivative financial instrument with value tied to an underlying company whose current operational status and detailed historical data are not readily accessible. Its strength relies entirely on the performance of the absent underlying entity, making it a high-risk, potentially high-reward investment dependent on information that is not currently public. It needs to look out for the re-emergence or clarification of its underlying company's status to determine any real value.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Publicly available financial data aggregators.
- Historical company filings (where applicable and identifiable).
Disclaimers:
The information provided is based on publicly available data and may not be exhaustive or entirely up-to-date. 'Biomotion Sciences Warrant' is a historical financial instrument, and its value and status are intrinsically linked to the performance and current standing of Biomotion Sciences, which is not clearly defined in current public records. Investors should conduct their own thorough due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomotion Sciences Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-16 | Chairman & CEO Mr. Ilan Hadar M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://silexion.com |
Full time employees 11 | Website https://silexion.com | ||
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 

